Home/Pipeline/Tmod-based Therapy

Tmod-based Therapy

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

A2 Biotherapeutics

About A2 Biotherapeutics

A2 Biotherapeutics is pioneering a differentiated approach to cell therapy with its Tmod™ platform, which uses a dual-signal 'activator/blocker' system to selectively target tumor cells based on genetic losses common in cancer. Founded in 2018, the private company is advancing a pipeline of autologous and allogeneic CAR T-cell therapies into clinical trials for solid tumors, a major unmet need. With strategic in-house manufacturing capabilities and an experienced leadership team, A2 Bio aims to overcome the toxicity limitations of current cell therapies and unlock new targets in oncology.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed